［1］Yin CZ,Nie MH.Clinicopathological analysis of patients with primary mucosal malignant melanoma of oral cavity［J］.General J Stomatol,2015,10(2):100-101.［尹崇志,聂敏海.口腔黏膜原发恶性黑色素瘤的临床病理分析［J］.全科口腔医学电子杂志,2015,10(2):100-101］.
[2]Xu HT,Han ZB,Zhang HL,et al.Effects of apigenin on growth,migration and angiogenesis of melanoma A375 cells and the mechanism［J］.China J Modern Med,2016,26(1):46-51.［徐红涛,韩中保,张慧丽,等.芹菜素对A375黑色素瘤生长、迁移和血管生成的影响及其作用机制［J］.中国现代医学杂志,2016,26(1):46-51.］
[3]Yang N,Zhang J,Sun KW.Diagnosis and treatment of malignant melanoma of the nasal cavity［J］.China Arch Otolaryngol Head Neck Surg,2016,23(4):237-238.［杨娜,张佳,孙克巍.鼻腔恶性黑色素瘤的确诊及治疗分析［J］.中国耳鼻咽喉头颈外科,2016,23(4):237-238.］
[4]Lundberg R,Brytting M,Dahlgren L,et al.Human herpes virus DNA is rarely detectedin non-UV light-associated primary malignant melanomas of mucous membranes［J］.Anticancer Res,2006,26(5B):3627-3631.
[5]Luo DT,Xia HS.Clinical and pathological characteristics of head and neck malignant melanoma［J］.Chin J Oncol,2001,23(3):80-82.［罗定泰,夏和顺.头颈部恶性黑色素瘤的临床及病理研究［J］.中华肿瘤杂志,2001,23(3):80-82.］
[6]Chang W,Lee SJ,Park S,et al.Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma［J］.Melanoma Res,2013,23:147-151.
[7]Shuang Y,Li C,Huang YW.Research progress of sentinel lymph node detection in head and neck cancer［J］.Chin J Ophthalmol and Otorhinolaryngol,2015,15(1):61-64.［双羽,李超,黄永望.前哨淋巴结检测在头颈部肿瘤中的研究进展［J］.中国眼耳鼻喉科杂志,2015,15(1):61-64.］
[8]Huang JT,Zeng JJ,Han ZD,et al.Magnetic resonance imaging in the diagnosis of non pigmented nasal melanoma［J］.China J Modern Med,2015,25(20):108-110.［黄剑涛,曾俊杰,韩再德,等.无色素性鼻腔黑色素瘤的磁共振成像诊断［J］.中国现代医学杂志,2015,25(20):108-110.］
[9]Zhou XQ,Yan L,Li Q,et al.Detection of CK，CD10 and Bcl － 2 in basal cell carcinoma and trichoblastoma［J］.Modern Oncology,2016,24(9):1450-1452.［周晓秋,燕丽,李青,等.联合检测CK、CD10和Bcl-2在皮肤基底细胞癌与毛母细胞瘤鉴别诊断中的应用［J］.现代肿瘤医学,2016,24(9):1450-1452.］
[10]Li SY,Wu KL,Lu W,et al.Early oral cancer cervical lymph node treatment［J］.J Practical Oncol,2015,30(1):8-11.［李思毅,吴开柳,陆伟,等.早期口腔癌颈部淋巴结处理［J］.实用肿瘤杂志,2015,30(1):8-11.］
[11]Zheng MF,Huang JN,Liu HS,et al.Diagnosis and treatment of sinonasal malignant melanoma in 22 cases［J］.Chin J Otorhinolaryngol-Skull Base Surg,2015,21(1):24-26.［郑明奋,黄健男,刘华盛,等.鼻腔鼻窦恶性黑色素瘤22例诊疗分析［J］.中国耳鼻咽喉颅底外科杂志,2015,21(1):24-26.］
[12]Menzies AM,Long GV.New combinations and immunotherapies formelanoma:Latest evidence and clinical utility［J］.Adv Med Oncol,2013,5:278-285.
[13]Liu WH,Sang MX,Shan BE.MAGE-A:New target of immunotherapy for esophageal cancer［J］.Cancer Res Prev Treat,2015,42(6):622-626.［刘维华,桑梅香,单保恩.黑色素瘤相关抗原-A:食管癌免疫治疗新靶点［J］.肿瘤防治研究,2015,42(6):622-626.］
[14]Pan JJ,Jia XQ,Huang G,et al.PD-1/PD-Ls signaling pathway and the application of anti-PD-1/PD-Lsantibodies in cancer therapy［J］.J China Pharmaceutical University,2016,47(1):9-18.［潘佳佳,贾晓青,黄岗,等.PD-1/PD-Ls信号通路及其抗体在肿瘤治疗中的应用［J］.中国药科大学学报,2016,47(1):9-18.］
[15]Gatalica Z,Snyder C,Maney T,et al.Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type［J］.Cancer Epidemiol Biomarkers Prev,2014,23:2965-2970.
[16]Velcheti V,Schalper KA,Carvajal DE,et al.Programmed death ligand-1 expression in non-small cell lung cancer［J］.Lab Invest,2014,94:107-116.
[17]Lv J,Guo W.Current status and development of head and neck melanoma treatments［J］.Chin J Clin Oncol,2015,42(16):841-844.［吕炯,郭伟.头颈部黑色素瘤治疗现状及进展［J］.中国肿瘤临床,2015,42(16):841-844.］
[18]Powles T,Eder JP,Fine GD,et al.MPDL3280A(anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer［J］.Nature,2014,515:558-562.
[19]Droeser RA,Hirt C,Viehl CT,et al.Clinical impact of programmed cell death ligand 1 expression in colorectal cancer［J］.Eur J Cancer,2013,49:2233-2242.